Dasatinib in Treating Patients With Stage IV Pancreatic Cancer

Stopped early · Phase 2

Conditions studied: Pancreatic Cancer

In brief

RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with stage IV pancreatic cancer.

Key facts

Study ID

NCT00544908

Run by

City of Hope Medical Center

People needed

7

Starts

2007-09-01

Last updated by the study team

2015-10-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• City of Hope Comprehensive Cancer Center — Duarte, California, United States
• City of Hope Medical Group — Pasadena, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.